Title:Montelukast Ameliorates 2K1C-Hypertension Induced Endothelial
Dysfunction and Associated Vascular Dementia
Volume: 20
Issue: 1
Author(s): Surbhi Gupta, Prabhat Singh*Bhupesh Sharma
Affiliation:
- Faculty of Pharmacy, Swami Vivekanand Subharti University, Meerut, Uttar Pradesh, India
Keywords:
Endothelium, hypertension, dementia, inflammation, montelukast, oxidative injury.
Abstract:
Background: Declined kidney function associated with hypertension is a danger for
cognitive deficits, dementia, and brain injury. Cognitive decline and vascular dementia (VaD)
are serious public health concerns, which highlights the urgent need for study on the risk factors
for cognitive decline. Cysteinyl leukotriene (CysLT1) receptors are concerned with regulating
cognition, motivation, inflammatory processes, and neurogenesis.
Objective: This research aims to examine the consequence of montelukast (specific CysLT1 antagonist)
in renovascular hypertension 2-kidney-1-clip-2K1C model-triggered VaD in experimental
animals.
Methods: 2K1C tactics were made to prompt renovascular hypertension in mature male rats.
Morris water maze was employed to measure cognition. Mean arterial pressure (MAP), serum
nitrite levels, aortic superoxide content, vascular endothelial activity, brain’s oxidative stress
(diminished glutathione, raised lipid peroxides), inflammatory markers (IL-10, IL-6, TNF-α),
cholinergic activity (raised acetylcholinesterase), and cerebral injury (staining of 2, 3, 5-
triphenylterazolium chloride) were also examined.
Results: Montelukast in doses of 5.0 and 10.0 mg kg-1 was used intraperitoneally as the treatment
drug. Along with cognitive deficits, 2K1C-operated rats showed elevated MAP, endothelial
dysfunction, brain oxidative stress, inflammation, and cerebral damage with diminished serum
nitrite/nitrate. Montelukast therapy significantly and dose-dependently mitigated the 2K1Chypertension-
provoked impaired behaviors, biochemistry, endothelial functions, and cerebral infarction.
Conclusion: The 2K1C tactic caused renovascular hypertension and associated VaD, which was
mitigated via targeted regulation of CysLT1 receptors by montelukast administration. Therefore,
montelukast may be taken into consideration for the evaluation of its complete potential in
renovascular-hypertension-induced VaD.
